CompletedNot Applicable

Long-term Follow-up Gene Therapy Study for RPGR- XLRP

United States, United Kingdom42 participantsStarted 2017-07-31

Plain-language summary

This is a long-term follow-up study assessing safety of patients for up to 60 months following advanced therapy investigational medicinal product (ATIMP) AAV5-hRKp.RPGR vector in participants with XLRP caused by mutations in RPGR.

Who can participate

Age range5 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Received AAV5-hRKp.RPGR in the MGT009 Study Exclusion Criteria: * Unwilling or unable to meet with the requirements of the study

What they're measuring

Assess the Longer-term Safety of AAV5-hRKp.RPGR Administered to Participants

Timeframe: 60 Months

Trial details

NCT IDNCT04312672

SponsorJanssen Research & Development, LLC

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-09-17

View on ClinicalTrials.gov More X-Linked Retinitis Pigmentosa trials